Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21


The comparative oncologic effectiveness of available management strategies for clinically localized prostate cancer.

Tyson MD, Penson DF, Resnick MJ.

Urol Oncol. 2017 Feb;35(2):51-58. doi: 10.1016/j.urolonc.2016.03.021. Epub 2016 Apr 28. Review.


Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2015 Nov;68(5):805-11. doi: 10.1016/j.eururo.2015.03.021. Epub 2015 Mar 21.


Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.

Seo WI, Kang PM, Kim TH, Moon KH, Chung JM, Lee DH, Kim IY, Min K, Chung J, Kim W, Kang DI.

World J Mens Health. 2014 Dec;32(3):159-66. doi: 10.5534/wjmh.2014.32.3.159. Epub 2014 Dec 29.


Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

Potosky AL, Haque R, Cassidy-Bushrow AE, Ulcickas Yood M, Jiang M, Tsai HT, Luta G, Keating NL, Smith MR, Van Den Eeden SK.

J Clin Oncol. 2014 May 1;32(13):1324-30. doi: 10.1200/JCO.2013.52.5782. Epub 2014 Mar 17.


Androgen deprivation therapy for treatment of localized prostate cancer and risk of second primary malignancies.

Wallner LP, Wang R, Jacobsen SJ, Haque R.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):313-6. doi: 10.1158/1055-9965.EPI-12-1137. Epub 2013 Jan 4.


An economic analysis of conservative management versus active treatment for men with localized prostate cancer.

Perlroth DJ, Bhattacharya J, Goldman DP, Garber AM.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):250-7. doi: 10.1093/jncimonographs/lgs037.


Obesity, energy balance, and cancer: new opportunities for prevention.

Hursting SD, Digiovanni J, Dannenberg AJ, Azrad M, Leroith D, Demark-Wahnefried W, Kakarala M, Brodie A, Berger NA.

Cancer Prev Res (Phila). 2012 Nov;5(11):1260-72. doi: 10.1158/1940-6207.CAPR-12-0140. Epub 2012 Oct 3. Review.


Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?

Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

Eur Urol. 2012 Dec;62(6):966-72. doi: 10.1016/j.eururo.2012.05.003. Epub 2012 May 10.


Metabolic complications and increased cardiovascular risks as a result of androgen deprivation therapy in men with prostate cancer.

Shastri BR, Yaturu S.

Prostate Cancer. 2011;2011:391576. doi: 10.1155/2011/391576. Epub 2011 Aug 1.


Low-dose diethylstilbestrol for the treatment of advanced prostate cancer.

Clemons J, Glodé LM, Gao D, Flaig TW.

Urol Oncol. 2013 Feb;31(2):198-204. doi: 10.1016/j.urolonc.2010.12.004. Epub 2011 Jul 27.


Testosterone regulates tight junction proteins and influences prostatic autoimmune responses.

Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS.

Horm Cancer. 2011 Jun;2(3):145-56. doi: 10.1007/s12672-010-0063-1.


Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer.

Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB.

J Natl Cancer Inst. 2010 Dec 1;102(23):1760-70. doi: 10.1093/jnci/djq419. Epub 2010 Nov 10.


Influence of gallate esterification on the activity of procyanidin B2 in androgen-dependent human prostate carcinoma LNCaP cells.

Chou SC, Kaur M, Thompson JA, Agarwal R, Agarwal C.

Pharm Res. 2010 Apr;27(4):619-27. doi: 10.1007/s11095-009-0037-6. Epub 2010 Feb 17.


Impact of ethnicity on primary treatment choice and mortality in men with prostate cancer: data from CaPSURE.

Moses KA, Paciorek AT, Penson DF, Carroll PR, Master VA.

J Clin Oncol. 2010 Feb 20;28(6):1069-74. doi: 10.1200/JCO.2009.26.2469. Epub 2010 Jan 25.


Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.

Gilbert SM, Kuo YF, Shahinian VB.

Urol Oncol. 2011 Nov-Dec;29(6):647-53. doi: 10.1016/j.urolonc.2009.09.004. Epub 2009 Nov 19.


Outcomes of localized prostate cancer following conservative management.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL.

JAMA. 2009 Sep 16;302(11):1202-9. doi: 10.1001/jama.2009.1348.


Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer.

Kuo YF, Goodwin JS, Shahinian VB.

BMC Health Serv Res. 2008 Jul 14;8:146. doi: 10.1186/1472-6963-8-146.


Survival following primary androgen deprivation therapy among men with localized prostate cancer.

Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL.

JAMA. 2008 Jul 9;300(2):173-81. doi: 10.1001/jama.300.2.173. Erratum in: JAMA. 2009 Jan 7;301(1):38.


Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M; Prostate Cancer Clinical Trials Working Group..

J Clin Oncol. 2008 Mar 1;26(7):1148-59. doi: 10.1200/JCO.2007.12.4487.

Supplemental Content

Support Center